Pharmacotherapy for Anxiety Disorders.
| Autor: | O'Leary KB; Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, 1 Baylor Plaza - BCM350, Houston, TX 77030, USA. Electronic address: Kerry.O'Leary@bcm.edu., Khan JS; Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, 1977 Butler Boulevard, E4.203. Houston, TX 77030, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Psychiatric clinics of North America [Psychiatr Clin North Am] 2024 Dec; Vol. 47 (4), pp. 689-709. Date of Electronic Publication: 2024 Jun 10. |
| DOI: | 10.1016/j.psc.2024.04.012 |
| Abstrakt: | Anxiety disorders are the most common psychiatric illness and include disorders such as generalized anxiety disorder (GAD), panic disorder (PD), and social anxiety disorder (SAD). Psychotherapy and pharmacotherapy are both effective treatments for anxiety disorders, with efficacy between 60% and 85%. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are first-line pharmacologic treatment for GAD, PD, and SAD. Recommendations for treating pediatric and geriatric populations vary slightly, but first-line treatments remain the same. Recent advancements in the treatment of anxiety disorders are limited although research has discovered novel pathways, which may lead to additional treatment options in the future. Competing Interests: Disclosure The authors have nothing to disclose. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|